Jiaotai pill enhances insulin signaling through phosphatidylinositol 3-kinase pathway in skeletal muscle of diabetic rats

Chinese Journal of Integrative Medicine

Volumn 19, Issue 9, 2013, Pages 668-674

  Dong, Hui ^a   Wang, Jian Hong ^a   Lu, Fu Er ^a   Xu, Li Jun ^a   Gong, Yan Lin ^a   Zou, Xin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chinese medicine; diabetes mellitus; insulin signaling; Jiaotai Pill; phosphatidylinositol 3 kinase; skeletal muscle

Indexed keywords

ANTIDIABETIC AGENT; CINNAMOMUM CASSIA EXTRACT; COPTIS CHINENSIS EXTRACT; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR BETA; INSULIN RECEPTOR SUBSTRATE 1; JIAOTAI PILL; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CINNAMON; CONTROLLED STUDY; DRUG FORMULATION; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PILL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SKELETAL MUSCLE;

ANIMALS; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DRUGS, CHINESE HERBAL; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 4; HOMEOSTASIS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MUSCLE, SKELETAL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN SUBUNITS; RATS; RATS, WISTAR; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84883284065     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-013-1560-1     Document Type: Article

References (38)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabet Care 2004;27:1047-1053.
2. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-2140.
3. Wong KC, Wang Z. Prevalence of type 2 diabetes mellitus of Chinese populations in Mainland China, Hong Kong, and Taiwan. Diabetes Res Clin Pract 2006;73:126-134.
4. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-1101.
5. Wang W, McGreevey WP, Fu C, Zhan S, Luan R, Chen W, et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care 2009;15:593-601.
6. Szoke E, Gerich JE. Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Compr Ther 2005;31:106-112.
7. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005;36:197-209.
8. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabet. Diabets Care 2009;32Suppl 2:S157-163.
9. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
10. Pirola L, Johnston AM, Van Obberghen E. Modulation of insulin action. Diabetologia 2004;47:170-184.
11. Peppa M, Koliaki C, Nikolopoulos P, Raptis SA. Skeletal muscle insulin resistance in endocrine disease. J Biomed Biotechnol 2010;2010:527850.
12. Hoffmann IS, Roa M, Torrico F, Cubeddu LX. Ondansetron and metformin-induced gastrointestinal side effects. Am J Ther 2003;10:447-451.
13. Reblin T. Thiazolidinedione use and the risk of fractures. CMAJ 2009;180:841.
14. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:592-600.
15. Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 2010;9:347-354.
16. Arnold N, McLean M, Chipps DR, Cheung NW. Effectiveness and side effects of thiazolidinediones for type 2 diabetes. Med J Aust 2005;182:494.
17. Scheen AJ. Thiazolidinediones and liver toxicity. Diabet Metab 2001;27:305-313.
18. Shadid S, Jensen MD. Angioneurotic edema as a side effect of pioglitazone. Diabet Care 2002;25:405.
19. Tang LQ, Wei W, Chen LM, Liu S. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 2006;108:109-115.
20. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93:2559-2265.
21. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712-717.
22. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010;59:285-292.
23. Kirkham S, Akilen R, Sharma S, Tsiami A. The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance. Diabetes Obes Metab 2009;11:1100-1113.
24. Crawford P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. J Am Board Fam Med 2009;22:507-512.
25. Leng SH, Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 2004;25:496-502.
26. Tremblay F, Lavigne C, Jacques H, Marette A. Dietary cod protein restores insulin-induced activation of phosphatidylinositol 3-kinase/Akt and GLUT4 translocation to the T-tubules in skeletal muscle of high-fat-fed obese rats. Diabetes 2003;52:29-37.
27. Kim EK, Kwon KB, Han MJ, Song MY, Lee JH, Lv N, et al. Coptidis rhizoma extract protects against cytokine-induced death of pancreatic beta-cells through suppression of NFkappaB activation. Exp Mol Med 2007;39:149-159.
28. Kwon KB, Kim EK, Lim JG, Shin BC, Han SC, Song BK, et al. Protective effect of Coptidis Rhizoma on S-nitroso-Nacetylpenicillamine (SNAP)-induced apoptosis and necrosis in pancreatic RINm5F cells. Life Sci 2005;76:917-929.
29. Imparl-Radosevich J, Deas S, Polansky MM, Baedke DA, Ingebritsen TS, Anderson RA, et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. Horm Res 1998;50:177-182.
30. Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabet Care 2003;26:3215-3218.
31. Pham AQ, Kourlas H, Pham DQ. Cinnamon supplementation in patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:595-599.
32. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991;40:1397-403.
33. Pascoe WS, Storlien LH. Inducement by fat feeding of basal hyperglycemia in rats with abnormal beta-cell function. Model for study of etiology and pathogenesis of NIDDM. Diabetes 1990;39:226-233.
34. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000;49:1390-1394.
35. Lan K, He JL, Tian Y, Tan F, Jiang XH, Wang L, et al. Intraherb pharmacokinetics interaction between quercetin and isorhamentin. Acta Pharmacol Sin 2008;29:1376-1382.
36. Zhou H, Wei L, Yang D. Determination of alkaloids in Coptis-Cinnamomum compatibility by capillary electrophoresis. China J Chin Mater Med (Chin) 1999;24:308-310,320.
37. Xu YC, Wei LX, Wang YL. Determination of cinnamic acid in Cinnamomum cassia presl after compatibility in Coptis chinensis Franch. China J Chin Mater Med (Chin) 2001;26:47-49.
38. Chen G, Lu FE, Wang F, Xu Li J, Zou X, Wang Kai F, et al. Effects of Rhizoma coptidis on relative bioavailability of cinnamic acid in Cinnamomum cassia. Chin Pharmaceut J (Chin) 2008;43:696-699.